A new review urges oncology researchers to treat patient-reported outcomes as core trial endpoints — not just secondary stats.
, Massimo Di Maio, MD, from the Department of Oncology at the University of Turin in Turin, Italy, and president-elect of the Italian Association of Medical Oncology, offers a detailed analysis of how patient-reported outcomes are used in clinical trials and explains the best practices for interpreting quality-of-life data.
a Medscape Network platform. “However, the scientific community is less familiar with interpreting — or critically assessing — this type of data compared with more traditional endpoints like progression-free survival or overall survival.” With growing support from scientific societies and regulatory agencies, QoL has become a standard endpoint in many studies. Yet practical guidance on its interpretation remains limited. Di Maio, who also served as lead author of the“We must not forget that for many patients — especially those in advanced stages of disease — living well can be just as important, if not more so, than living longer,” he emphasized. He also cautioned that statistical significance does not always translate into meaningful clinical benefit.To accurately assess QoL and maximize the value of the data, clinical trials must be appropriately designed from the outset. As outlined in the article, phase 3 randomized trials offer the ideal framework for QoL measurement. They allow investigators to compare results between treatment and control groups, tracking changes from baseline and over time. Di Maio explains in the review that randomized trial designs help ensure that any differences observed between study arms are directly linked to the treatment itself., he also addressed the potential for bias in QoL data collection. “Some researchers argue that simply knowing they are receiving the experimental treatment may lead patients — perhaps even subconsciously — to perceive a benefit, which could influence patient-reported outcomes like QoL,” he said. Still, Di Maio noted the difficulty in rigorously proving the existence or magnitude of such bias. Ideally, this would be tested by comparing blinded and open-label trials, but these studies are uncommon and logistically challenging. One, led by Fabio Efficace, PhD, of the Italian Group for Adult Hematologic Diseases, found that trial blinding was not an independent predictor of QoL benefit. While the potential for bias cannot be dismissed, Di Maio believes its real-world impact is likely modest — and that open-label studies can still yield valid and meaningful QoL data.Few oncology trials designate QoL as a primary endpoint, but this isn't inherently a limitation, Di Maio noted. QoL can still be a valuable secondary endpoint — provided the results are interpreted carefully and in the proper context. One of the central challenges is patient compliance with QoL questionnaires, which tends to be inconsistent. Factors contributing to low completion rates include limited time for clinicians to communicate the importance of QoL data, patient dropout due to disease progression or adverse outcomes, and technical issues such as failures in electronic data capture or patients’ unfamiliarity with digital tools. In such cases, Di Maio suggested that having a paper-based backup system can improve data reliability. Ultimately, QoL should not be viewed as an optional or secondary concern, but as a fundamental part of assessing the true value of cancer therapies. Patient-reported outcome measures, while designed to capture quality of life, also offer critical insights into the broader effectiveness and utility of treatments. “QoL data alone aren’t sufficient,” Di Maio emphasized, “but they are indispensable for understanding the value of a therapy — and for communicating that value clearly to patients.” He concluded that interpreting QoL data accurately is not just a scientific imperative but also an ethical obligation to patients navigating serious and often life-limiting conditions.Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our
Medical Informatics Medical Informatics Applications Health Informatics Drug/Treatment Safety Drug Safety Treatment Safety Drug Development Drug Discovery Drug Pipeline Drug Development Pipeline U.S. Food And Drug Administration United States Food And Drug Administration FDA Food And Drug Administration (FDA) Food And Drug Administration Cancer Malignant Neoplasia
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
50 Things To Transform Your BackyardBecause your backyard deserves to be the main character this summer.
Read more »
This Dark Fantasy Action-RPG Deserves To Be Top Of Your Wishlist After Gameplay RevealNicholas Becher is a writer/editor based out of Connecticut. Most-played games include Elden Ring, Clair Obscur, and BG3.
Read more »
The Best TV Episode Of All Time Aired 12 Years Ago And Deserves Its Masterpiece StatusThe Best TV Episode Of All Time Aired 12 Years Ago
Read more »
Eagles’ Nick Sirianni still not getting respect he deserves after leading team to Super Bowl titleThis is the time of year that coaching and player rankings come out and Sirianni was pretty far down the list for a man who just led his team to the Super Bowl.
Read more »
Keke Palmer's Chrome Manicure Deserves a Gold StarDanielle Jackson is the senior beauty writer at Marie Claire. She has nearly a decade of experience covering beauty, lifestyle, and entertainment and was previously the senior beauty editor at Women's Health, where she thoughtfully covered topics related to skincare, haircare, aesthetics, and wellness.
Read more »
Trimodal Therapy Costs Offset QOL Benefit in Muscle-Invasive Bladder CancerTrimodal therapy improves quality of life compared with radical cystectomy in patients with muscle-invasive bladder cancer but is not cost-effective.
Read more »